Rupatadine

• CAT Number: I002017
• CAS Number: 158876-82-5
• Molecular Formula: C26H26ClN3
• Molecular Weight: 415.96
• Purity: ≥95%
• Target: Neuronal Signaling
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: 13-chloro-2-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene]-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
• InChI: InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3
• InChIKey: WUZYKBABMWJHDL-UHFFFAOYSA-N
• SMILES: CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2

Rupatadine（Cat No.:I002017）is a second-generation antihistamine primarily used to treat allergic rhinitis and chronic urticaria. It acts by selectively blocking H1 histamine receptors, effectively alleviating symptoms such as sneezing, runny nose, and itchy eyes associated with allergies. In addition to its antihistaminic effects, rupatadine possesses anti-inflammatory properties by inhibiting the release of pro-inflammatory mediators, contributing to its overall therapeutic action. Its favorable safety profile minimizes the risk of sedation, making it suitable for daily use. Rupatadine’s efficacy and tolerability make it a valuable option for managing allergic conditions.

Reference

[1]. Merlos M, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997 Jan;280(1):114-21.
[2]. Queralt M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000 Jul;49(7):355-60.
[3]. Lv XX, et al. Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents. PLoS One. 2013 Jul 15;8(7):e68631.